Bio-Techne Corp (NASDAQ:TECH) — Market Cap & Net Worth
Market Cap & Net Worth: Bio-Techne Corp (TECH)
Bio-Techne Corp (NASDAQ:TECH) has a market capitalization of $8.24 Billion ($8.24 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2617 globally and #940 in its home market, demonstrating a 8.04% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bio-Techne Corp's stock price $56.17 by its total outstanding shares 156568751 (156.57 Million). Review Bio-Techne Corp balance sheet liabilities to assess the company's total debt and financial obligations.
Bio-Techne Corp Market Cap History: 2015 to 2026
Bio-Techne Corp's market capitalization history from 2015 to 2026. Data shows growth from $3.31 Billion to $8.79 Billion (8.99% CAGR).
Index Memberships
Bio-Techne Corp is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.08 Trillion | 0.76% | #16 of 39 |
|
S&P 500 Index
GSPC
|
$62.29 Trillion | 0.02% | #478 of 503 |
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.34% | #54 of 976 |
|
NASDAQ Composite
IXIC
|
$41.39 Trillion | 0.02% | #299 of 3165 |
Weight: Bio-Techne Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bio-Techne Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bio-Techne Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.55x
Bio-Techne Corp's market cap is 7.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
125.45x
Bio-Techne Corp's market cap is 125.45 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.83 Billion | $499.02 Million | $104.48 Million | 7.67x | 36.66x |
| 2017 | $4.88 Billion | $563.00 Million | $77.29 Million | 8.67x | 63.13x |
| 2018 | $5.49 Billion | $642.99 Million | $125.35 Million | 8.54x | 43.83x |
| 2019 | $8.39 Billion | $714.01 Million | $96.07 Million | 11.75x | 87.31x |
| 2020 | $12.20 Billion | $738.69 Million | $229.30 Million | 16.51x | 53.19x |
| 2021 | $19.93 Billion | $931.03 Million | $140.41 Million | 21.40x | 141.93x |
| 2022 | $12.86 Billion | $1.11 Billion | $272.05 Million | 11.64x | 47.29x |
| 2023 | $12.03 Billion | $1.14 Billion | $285.26 Million | 10.58x | 42.17x |
| 2024 | $11.28 Billion | $1.16 Billion | $168.10 Million | 9.73x | 67.09x |
| 2025 | $9.21 Billion | $1.22 Billion | $73.40 Million | 7.55x | 125.45x |
Competitor Companies of TECH by Market Capitalization
Companies near Bio-Techne Corp in the global market cap rankings as of June 17, 2026.
Key companies related to Bio-Techne Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Bio-Techne Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Bio-Techne Corp's market cap moved from $3.31 Billion to $ 8.79 Billion, with a yearly change of 8.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.79 Billion | -4.49% |
| 2025 | $9.21 Billion | -18.35% |
| 2024 | $11.28 Billion | -6.25% |
| 2023 | $12.03 Billion | -6.49% |
| 2022 | $12.86 Billion | -35.45% |
| 2021 | $19.93 Billion | +63.40% |
| 2020 | $12.20 Billion | +45.40% |
| 2019 | $8.39 Billion | +52.67% |
| 2018 | $5.49 Billion | +12.60% |
| 2017 | $4.88 Billion | +27.40% |
| 2016 | $3.83 Billion | +15.77% |
| 2015 | $3.31 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Bio-Techne Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.24 Billion USD |
| MoneyControl | $8.24 Billion USD |
| MarketWatch | $8.24 Billion USD |
| marketcap.company | $8.24 Billion USD |
| Reuters | $8.24 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various asp… Read more